KDOQI (Kidney Disease Outcomes Quality Initiative)


NKF KDOQI GUIDELINES

Published KDOQI Guidelines Are Available Online – click here.
www.kdoqi.org

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease


TABLES

Table 1. Goals for CVD Risk Factor Management in Patients With Diabetes
Table 2. Diagnostic Testing for Coronary Heart Disease in Diabetes
Table 3. Definitions of Abnormalities in Albumin Excretion
Table 4. Albuminuria as a Predictor of Albuminuria Progression in Type 1 Diabetes
Table 5. Albuminuria as a Predictor of Albuminuria Progression in Type 2 Diabetes
Table 6. Likelihood of DKD According to Staging by GFR and Level of Albuminuria
Table 7. Albuminuria as a Predictor of DKD Progression, CVD, and Mortality in Type 1 Diabetes
Table 8. Albuminuria as a Predictor of DKD Progression, CVD, and Mortality in Type 2 Diabetes
Table 9. Relationship Between Albuminuria and Kidney Morphology in Type 1 Diabetes
Table 10. Relationship Between Kidney Function and Morphology in Type 1 Diabetes
Table 11. Relationship Between Albuminuria and Kidney Morphology in Type 2 Diabetes
Table 12. Relationship Between Kidney Function and Morphology in Type 2 Diabetes
Table 13. Predictive Value of Diabetic Retinopathy for Diagnosis of DKD in Biopsy Studies
Table 14. Strategies to Prevent Bleeding After Kidney Biopsy
Table 15. Observed Incidence of Acute Kidney Failure After PCI That Included Administration of Radiocontrast, Stratified by Baseline Serum Creatinine and Diabetes Status
Table 16. Effect of Interventions to Decrease the Risk of RCN in People With Diabetes and CKD Undergoing Angiographic Procedures
Table 17. Type of Radiocontrast Agent and Risk of RCN in Diabetes and/or CKD
Table 18. Preventive Strategies for RCN
Table 19. Effect of Glycemic Control on Kidney Function and Albuminuria in Type 1 Diabetes
Table 20. Effect of Glycemic Control on Kidney Function and Albuminuria in Type 2 Diabetes
Table 21. Effect of TZDs on Albuminuria, Glycemia, and Blood Pressure in Type 2 Diabetes
Table 22. Dosing Adjustments by CKD Stage for Drugs Used to Treat Hyperglycemia
Table 23. Insulin Preparations Categorized by Duration of Effect
Table 24. Clinically Relevant Interactions With Drugs Used to Treat Hyperglycemia
Table 25. ADA Standards for Assessment of Glycemic Control
Table 26. ADA Standards for Assessment of Retinopathy and Foot Care
Table 27. Hypertension and Antihypertensive Agents in DKD
Table 28. Doses of ACE Inhibitors and ARBs for Adults
Table 29. Prevalence of Hypertension in DKD
Table 30. Effect of Antihypertensive Agents on CKD and Hypertension in Type 1 and Type 2 Diabetes
Table 31. Effect of Different Blood Pressure Targets on CKD in Type 1 and Type 2 Diabetes
Table 32. Summary of Number of Antihypertensive Agents Required to Reach Target Blood Pressure
Table 33. Recommended Intervals for Follow-Up Evaluation of Blood Pressure, GFR, and Potassium
Table 34. Effect of Lipid-Lowering Treatments on Kidney Function and Albuminuria in Type 1 and Type 2 Diabetes
Table 35. Dosing Adjustments of Medicines to Treat Lipid Disorders in CKD
Table 36. NKF-KDOQI™ CPGs for Managing Dyslipidemia in CKD Stages 1 to 4
Table 37. Effect of Low-Protein Diets on Mortality, Kidney Function, Albuminuria, and Risk Factors in Type 1 Diabetes
Table 38. Effect of Low-Protein Diets on Kidney Function, Albuminuria, and Risk Factors in Type 2 Diabetes
Table 39. Effect of Miscellaneous Diets on Kidney Function, Albuminuria, and Risk Factors in Type 1 Diabetes
Table 40. Effect of Miscellaneous Diets on Mortality, Kidney Function, Albuminuria, and Risk Factors in Type 2 Diabetes
Table 41. Effect of Fatty Acid Supplements on Kidney Function, Albuminuria, and Risk Factors in Type 1 and Type 2 Diabetes
Table 42. Key Studies Evaluating Effects of Dietary Protein Restriction or Other Alterations on Kidney Outcomes in Patients With Diabetes and CKD
Table 43. A Balanced Approach to Nutrition in CKD With or Without Diabetes: Macronutrient Composition and Mineral Content
Table 44. Effect of ACE Inhibitors on Mortality, CVD, Kidney Function, Albuminuria, and Miscellaneous Outcomes in Type 2 Diabetes
Table 45. Effect of ARBs on Mortality, Kidney Function, and Albuminuria in Type 2 Diabetes
Table 46. Effect of ARBs versus ACE Inhibitors on Kidney Function and Albuminuria in Type 2 Diabetes
Table 47. Effect of Miscellaneous Treatments on Mortality, Kidney Function, and Albuminuria in Type 2 Diabetes
Table 48. Summary of Steno Trial Multifaceted Intervention for Diabetes and CKD
Table 49. Proposed Mechanisms for Associations Between Obesity and CKD
Table 50. Countries With the Highest Numbers of Estimated Cases of Diabetes for 2000 and 2030.
Table 51. Plasma Blood Glucose and HbA1c Goals for Type 1 Diabetes by Age Group.
Table 52. Adverse Maternal and Child Outcomes in Pregnancies Complicated by Diabetes and CKD
Table 53. Predictors of Adverse Maternal and Child Outcomes in Pregnancies Complicated by Diabetes and CKD
Table 54. Management of Pregnant Women With Diabetes and CKD
Table 55. Systematic Reviews of Behavioral Studies in People With Diabetes
Table 56. Components and Principles of a Diabetes and CKD Self-Management Education Program
Table 57. Self-Management Principles
Table 58. Nutrient Composition of This Full-Day Meal Plan
Table 59. Topics for Which Systematic Reviews of Primary Studies Were Performed
Table 60. Format for Guidelines
Table 61. Rating the Strength of Guideline and CPR Statements
Table 62. Rating the Quality of Evidence
 

Back to top | Main Page